Welcome to our dedicated page for ALBEMARLE SEC filings (Ticker: ALB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Albemarle Corporation filings document operating results, material events, governance matters, shareholder voting items, and capital-structure disclosures for a public specialty chemicals and critical materials company. Form 8-K reports cover quarterly financial results, credit agreement amendments, debt-related actions, board appointments, officer transitions, and completed portfolio transactions.
Proxy materials describe director elections, committee governance, executive compensation, shareholder proposals, and voting procedures. Albemarle's filing record also documents the completed disposition of a controlling stake in Ketjen, retained ownership interests, integration of Performance Catalyst Solutions, and financing arrangements tied to the company's global lithium, bromine and specialty product businesses.
Albemarle Corporation (ALB) reported a narrower quarterly loss as lithium markets remain weak but cash generation improved. For Q3, net sales were $1,307.8 million versus $1,354.7 million a year ago. Operating loss was $216.986 million, including a non-cash $181.1 million goodwill impairment tied to the Refining Solutions reporting unit. Net loss attributable to common shareholders was $202.4 million, or $1.72 per share, compared with a $1.1107 billion loss, or $9.45 per share, last year.
Gross profit improved to $117.6 million from a loss last year as cost actions and lower inventory charges helped. Equity income from unconsolidated investments contributed $60.6 million, led by Windfield. Year to date, operating cash flow rose to $893.8 million, capital expenditures fell to $434.4 million, and cash ended at $1.932 billion. The company recorded $350 million of deferred revenue from a customer for future deliveries of spodumene and lithium salts over five years.
Inventory valuation adjustments declined to $11.1 million as of September 30, 2025. Shares outstanding were 117,697,540 as of October 29, 2025.
Albemarle Corporation furnished an update on its business by issuing a press release reporting results for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1 to an Item 2.02 current report. The Company will host an analyst and media teleconference on November 6, 2025, with a webcast available at www.albemarle.com. The information in this report, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act.
Albemarle Corporation (ALB): Schedule 13G/A (Amendment No. 2) discloses that Franklin Resources, Inc. and affiliates reported beneficial ownership of 6,853,257 common shares, representing 5.7% of the class as of September 30, 2025. The filing states this includes 3,551,809 shares issuable on conversion of debt securities under Rule 13d‑3(d)(1)(i).
Franklin Advisers, Inc. reports 6,088,726 shares, or 5.0%, with sole voting and dispositive power over that amount. For Franklin Resources, the filing lists sole voting power 6,463,983 and shared voting power 62,493; sole dispositive power 6,790,597 and shared dispositive power 62,660. Charles B. Johnson and Rupert H. Johnson, Jr. each report 0 shares.
The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing control.
Albemarle (ALB) Form 4: The company’s General Counsel & Secretary reported a sale of 172 shares of common stock on 10/24/2025 at $105 per share (Transaction Code: S). The filing states the trade was executed under a Rule 10b5-1 trading plan adopted on March 13, 2025, prior to the individual becoming an executive officer. Following the transaction, the insider directly holds 11,483 shares.
Albemarle (ALB) agreed to sell and contribute its Ketjen business into a new structure with KPS affiliates, receiving an estimated $536 million in cash at closing and retaining Rollover Equity initially representing a 49% interest in Holdco. The purchase price framework values the purchased shares at $800.0 million less the value ascribed to the contributed shares, subject to customary closing adjustments. The transaction is expected to close in the first half of 2026, subject to regulatory approvals and other conditions.
Separately, Ketjen agreed to sell its interest in Eurecat S.A. for €105 million (approximately $125 million). Albemarle expects approximately $660 million in aggregate cash proceeds from both transactions, to be used for debt reduction and general corporate purposes. Albemarle also expects a non-cash goodwill impairment charge of $181.5 million in Q3 2025 tied to the Refining Solutions reporting unit.
The agreement includes an Outside Date of April 30, 2026 and a potential $32.5 million termination fee payable to Albemarle by the purchaser under specified circumstances.
Albemarle Corporation (ALB) reported an insider transaction. On 10/09/2025, the company’s General Counsel & Secretary sold 116 shares of common stock at $95 per share in a transaction reported on Form 4. Following the sale, the reporting person beneficially owned 11,655 shares, held directly.
The filing notes the sale was made under a Rule 10b5-1 trading plan adopted on March 13, 2025, prior to the individual becoming an Executive Officer.
Albemarle Corporation filed a specialized disclosure report as a resource extraction issuer under Rule 13q-1 for the fiscal year ended December 31, 2024. The company provides a consolidated overview of payments to governments made by Albemarle and its consolidated subsidiaries for that year. The detailed payment information is contained in a separate Resource Extraction Payment Report, which is filed as Exhibit 2.01 to this Form SD.
Initial Form 3 filing by Autumn M. Gagarinas for Albemarle Corporation (ALB). The report shows direct beneficial ownership of 4,054 common shares and disclosure of restricted stock units and stock options. Total RSUs disclosed vest between 2026 and 2028 and two option grants exercisable in 2027 and 2028 with expiration in 2034 and 2035. Ownership is reported in the filer\'s capacity as Chief People Officer.
Capital Research Global Investors filed a Schedule 13G reporting beneficial ownership of 6,307,813 shares of Albemarle Corporation common stock, representing 5.3% of the 119,818,504 shares believed outstanding as of the reporting event date. The filing notes that reported holdings include 4,721,204 Convertible Preferred Stocks, which the filer states represent 2,157,590 common shares.
The submission identifies CRGI as an investment management division and includes a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The filing is signed by Jae Won Chung on 08/05/2025 and lists issuer and filer addresses.
Albemarle Corporation announced an organizational change in which Netha N. Johnson, the company's Chief Operations Officer, left effective August 10, 2025, and Mark M. Mummert succeeded her as Chief Operations Officer effective August 11, 2025. Mr. Mummert joined Albemarle in 2019, has led the Energy Storage operating unit and capital projects, and brings prior supply chain and manufacturing experience from FMC, Rohm and Haas, and Dow.
The company disclosed Mr. Mummert's material compensation terms: an annual base salary of $550,000, continued participation in the annual incentive plan at a target of 80% of eligible earnings, a 2026 long-term incentive award with a $1,400,000 target value to be granted in Q1 2026, and standard executive benefits eligibility.